MICROBIX BIOSYSTEMS INC (MBX.CA) Stock Price, Forecast & Analysis
TSX:MBX • CA59501P1045
MBX.CA Key Statistics, Chart & Performance
The current stock price of MBX.CA is 0.22 CAD. In the past month the price decreased by -8.33%. In the past year, price decreased by -60%.
MBX.CA Technical Analysis
MBX.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to MBX.CA. MBX.CA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MBX.CA Financial Highlights
Over the last trailing twelve months MBX.CA reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS decreased by -163.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -6% | ||
| ROE | -8.08% | ||
| Debt/Equity | 0.24 |
MBX.CA Forecast & Estimates
5 analysts have analysed MBX.CA and the average price target is 0.51 CAD. This implies a price increase of 131.82% is expected in the next year compared to the current price of 0.22.
For the next year, analysts expect an EPS growth of 33.33% and a revenue growth 35.93% for MBX.CA
MBX.CA Ownership
MBX.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 596.271M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 380.328M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 141.303M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 69.23M | ||
| COV | COVALON TECHNOLOGIES LTD | 13.11 | 44.744M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 39.875M | ||
| RVX | RESVERLOGIX CORP | N/A | 27.318M | ||
| HEM | HEMOSTEMIX INC | N/A | 17.573M | ||
| MPH | MEDICURE INC | N/A | 11.693M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About MBX.CA
Company Profile
Microbix Biosystems, Inc. engages in developing and commercializing proprietary biological and technology solutions for human health and wellbeing. The company is headquartered in Mississauga, Ontario. The firm develops and commercializes proprietary biological and technology solutions for human health and wellbeing. The company manufactures a range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays, quality assessment and proficiency testing controls (QAPsTM business), and sample collection devices (DxTMTM business). The firm operates in two ways: (i) the development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples, and (ii) the development and commercialization of novel and proprietary products or technologies such as Kinlytic. It's Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots.
Company Info
MICROBIX BIOSYSTEMS INC
265 Watline Avenue
Mississauga ONTARIO L4Z 1P3 CA
CEO: Cameron Groome
Employees: 0
Phone: 19053618910
MICROBIX BIOSYSTEMS INC / MBX.CA FAQ
What does MICROBIX BIOSYSTEMS INC do?
Microbix Biosystems, Inc. engages in developing and commercializing proprietary biological and technology solutions for human health and wellbeing. The company is headquartered in Mississauga, Ontario. The firm develops and commercializes proprietary biological and technology solutions for human health and wellbeing. The company manufactures a range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays, quality assessment and proficiency testing controls (QAPsTM business), and sample collection devices (DxTMTM business). The firm operates in two ways: (i) the development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples, and (ii) the development and commercialization of novel and proprietary products or technologies such as Kinlytic. It's Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots.
What is the stock price of MICROBIX BIOSYSTEMS INC today?
The current stock price of MBX.CA is 0.22 CAD. The price decreased by -2.22% in the last trading session.
Does MBX stock pay dividends?
MBX.CA does not pay a dividend.
What is the ChartMill rating of MICROBIX BIOSYSTEMS INC stock?
MBX.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the sector and industry classification for MICROBIX BIOSYSTEMS INC?
MICROBIX BIOSYSTEMS INC (MBX.CA) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of MBX stock?
MICROBIX BIOSYSTEMS INC (MBX.CA) has a market capitalization of 30.48M CAD. This makes MBX.CA a Nano Cap stock.
Can you provide the upcoming earnings date for MICROBIX BIOSYSTEMS INC?
MICROBIX BIOSYSTEMS INC (MBX.CA) will report earnings on 2026-05-13.